At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
VH3810109 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Single-Dose Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, GSK3810109, Administered Either Subcutaneously or Intravenously With Recombinant Human Hyaluronidase PH20 (rHuPH20) to Healthy Adults
In Brief
A Phase 1 clinical trial evaluating VH3810109 and rHuPH20 for HIV Infections. Completed, enrolled 24 participants across 1 site.
Detailed Summary
An open-label, two part study to assess the safety, tolerability, and PK of VH3810109 in healthy adult participants. Participants will receive a single SC or IV dose of VH3810109 co-administered with rHuPH20 and will be followed up for 24 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartFeb 2022
First PostedMar 2022
Primary CompletionApr 2023
TodayJul 2026
First PostedMar 22, 2022
Enrollment StartFeb 23, 2022
Primary CompletionApr 10, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.3 years ago
Interventions
VH3810109biological
VH3810109 was administered.
rHuPH20biological
rHuPH20 was administered.